IceCure enrolls first two patients in FDA-approved ProSense breast cancer cryoablation ChoICE Study at two U.S. sites
IceCure Medical announced that the first two patients have been enrolled at two U.S. clinical sites in the post-marketing ChoICE Study evaluating ProSense cryoablation for local treatment of low-risk breast cancer. The first patient was enrolled at West Cancer Center & Research Institute in Germantown, Tennessee by Dr. Richard E. Fine, and the second at Adventist Health Glendale in Glendale, California under Dr. Dennis Holmes. The study is designed to enroll approximately 400 patients across up to 30 U.S. clinic...
Key takeaways
First two patients enrolled in the post-marketing ChoICE Study of ProSense breast cancer cryoablation at two U.S. sites
First enrollment site: West Cancer Center & Research Institute, Germantown, Tennessee, led by Dr. Richard E. Fine, MD, FACS
Second enrollment site: Adventist Health Glendale, Glendale, California, led by Dr. Dennis Holmes, MD, FACS
ChoICE Study designed to enroll approximately 400 patients across up to 30 U.S. clinical sites
Both sites signed site agreements and received IRB approval in August 2026; Legacy Medical Group at Good Samaritan Medical Center in Portland, Oregon was added earlier in October 2026
ProSense is described as the first and only medical device cleared by the FDA for local treatment of breast cancer in patients aged 70 years and older with biologically low-risk tumors ≤1.5 cm receiving adjuvant endocrine therapy
Participating sites are intended to serve as both study centers and active commercial sites offering ProSense to eligible non-study patients
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow ICCM in real time
Get material earnings, filing, IR, and earnings-call alerts by email.